-
Methotrexate: From DHFR Biology to Translation
2026-08-24
Methotrexate is more than a conventional folate antagonist: it is a mechanistic benchmark for connecting DHFR inhibition, intracellular polyglutamation, activated T-cell apoptosis, and inflammation biology. This translational guide shows how to deploy Methotrexate rigorously in psoriasis-related research while avoiding common interpretation and workflow pitfalls.
-
MDA in Ferroptosis: From Signal to Strategy
2026-08-23
Malondialdehyde quantification is evolving from a generic oxidative stress endpoint into a strategic tool for studying ferroptosis, drug resistance, and translational biomarker design. This article connects the OTUD3–SLC7A11 mechanism in clear cell renal cell carcinoma with practical assay planning and evidence-aware deployment of the Lipid Peroxidation (MDA) Assay Kit.
-
Y-27632 Workflows for ROCK Signaling Research
2026-08-22
Y-27632 provides reversible, selective ROCK1 and ROCK2 inhibition for separating cytoskeletal effects from broader cellular responses. This guide applies it to stress-fiber assays, migratory interneuron models, and glioma-focused workflows while emphasizing dose control, vehicle matching, and interpretation limits.
-
hiPSC Intestinal Organoids for Pharmacokinetics
2026-08-22
Saito and colleagues established a direct three-dimensional culture strategy for generating expandable human iPSC-derived intestinal organoids. The resulting organoids can be maintained, cryopreserved, and differentiated into intestinal epithelial cells with drug-metabolizing enzyme and transporter activities, creating a more human-relevant platform for pharmacokinetic studies.
-
Molidustat Workflows for HIF Hypoxia Research
2026-08-21
Molidustat (BAY85-3934) gives researchers a controllable way to probe HIF stabilization, endogenous erythropoietin stimulation, and hypoxia-related cell injury. This workflow connects renal anemia research with a Septin4–VHL–HIF-1α mechanism while clearly separating established evidence from exploratory cardiovascular applications.
-
Lumiracoxib Workflows for COX-2 Research
2026-08-20
Lumiracoxib enables selective COX-2 pathway modulation across prostaglandin, inflammation, and muscle revascularization assays. Its greatest experimental value is temporal: the reference study shows that early and delayed inhibition can produce different vascular outcomes.
-
Epacadostat (INCB024360) Assay Workflows
2026-08-20
Learn how to deploy Epacadostat as a mechanistic IDO1 probe across biochemical, cellular, and standardized whole-blood assays. The workflow connects kynurenine-pathway measurements with cytokine and T-cell functional readouts, helping immuno-oncology researchers distinguish target engagement from nonspecific immune suppression.
-
Viral vIRD Control of RIPK3 and Inflammation
2026-08-19
Liu et al. identified a cowpox virus and orthopoxvirus factor, termed vIRD, that recruits host SCF machinery to drive ubiquitination and proteasomal degradation of RIPK3. Genetic and mouse infection experiments showed that this immune-evasion mechanism shapes necroptosis, inflammation, viral replication, and mortality in a RIPK3- and MLKL-dependent manner.
-
HyperScript RT SuperMix for qPCR Workflow
2026-08-19
Build a robust two-step qRT-PCR workflow for macrophage signaling, sepsis-induced acute lung injury, and low-input RNA samples. HyperScript™ RT SuperMix for qPCR combines a thermostable HyperScript Reverse Transcriptase with mixed priming to support reproducible cDNA synthesis for qPCR when RNA structure or limited sample volume is a concern.
-
COX-2, Ischemia, and Revascularization After Venom Injury
2026-08-18
This study identifies a time-dependent role for cyclooxygenase-2 (COX-2) in skeletal muscle injury caused by Bothrops asper venom: early COX-2 activity helps preserve vascular integrity, whereas early inhibition later increases proangiogenic signaling. The findings show why temporal control, rather than blanket suppression, is essential when interpreting COX-2 pathway modulation in muscle ischemia and repair.
-
(-)-Blebbistatin in Cardiac Mechanobiology
2026-08-18
Explore how (-)-Blebbistatin, a reversible non-muscle myosin II inhibitor, can be paired with transparent multimodal cardiac bioelectronics to connect actin-myosin remodeling with electrical and metabolic physiology.
-
Y-27632: Practical ROCK Inhibitor Workflow
2026-08-17
Y-27632 provides a reversible, ATP-competitive way to perturb ROCK1 and ROCK2 activity in biochemical and cell-based assays, helping researchers examine cytoskeletal organization and ROCK signaling pathway research. Use it as an experimental pathway-perturbation tool rather than as a universal viability enhancer, clinical agent, or substitute for matched controls and assay-specific optimization.
-
Lumiracoxib: Designing Better COX-2 Assays
2026-08-17
Lumiracoxib is a selective COX-2 inhibitor that can do more than suppress prostaglandin production. This article shows how to use its temporal pharmacology, chemical properties, and vascular-repair findings to design more interpretable inflammation and revascularization assays.
-
WM-8014: From KAT6A Mechanism to Translation
2026-08-16
WM-8014 connects competitive KAT6A/B inhibition with cell-cycle arrest, senescence, and oncogene-driven overproliferation. This thought-leadership guide shows how to use the compound as a mechanistic probe while accounting for selectivity, formulation, model maturity, and translational limitations.
-
Bestatin (Ubenimex): From Active Site to Translation
2026-08-15
Bestatin (Ubenimex) is more than a catalog inhibitor: its zinc-enzyme structural biology, selectivity profile, and cell-based precedents make it a useful bridge between aminopeptidase mechanism and translational research. This article presents a strategy for pairing biochemical validation, aminopeptidase activity measurement, apoptosis assays, and multidrug resistance research without overextending preclinical evidence.